

**ADYPHREN II KIT- epinephrine and isopropyl alcohol**  
**Asclemed USA, Inc.**

*Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.*

-----

**HIGHLIGHTS OF PRESCRIBING INFORMATION**

**These highlights do not include all the information needed to use ADRENALIN safely and effectively. See full prescribing information for ADRENALIN. ADRENALIN (epinephrine injection) 1 mg/mL, for intramuscular, subcutaneous, and intravenous use Initial U.S. Approval: 1939**

-----  
**RECENT MAJOR CHANGES**

Dosage and Administration (2.1) 05/2016  
Warnings and Precautions (5.3, 5.4) 05/2016

-----  
**INDICATIONS AND USAGE**

Adrenalin<sup>®</sup> is a non-selective alpha and beta adrenergic agonist indicated for:

- Emergency treatment of allergic reactions (Type 1), including anaphylaxis (Adrenalin<sup>®</sup> 1 mL vials) ( 1.1)
- Induction and maintenance of mydriasis during intraocular surgery (Adrenalin<sup>®</sup> 1 mL vial only) ( 1.2)

-----  
**DOSAGE AND ADMINISTRATION**

- Anaphylaxis (Adrenalin<sup>®</sup> 1 mL vials):
  - *Adults and Children 30 kg (66 lbs) or more:* 0.3 to 0.5 mg (0.3 to 0.5 mL) intramuscularly or subcutaneously into anterolateral aspect of the thigh every 5 to 10 minutes as necessary ( 2.1)
  - *Children 30 kg (66 lbs) or less:* 0.01 mg/kg (0.01 mL/kg), up to 0.3 mg (0.3 mL), intramuscularly or subcutaneously into anterolateral aspect of the thigh every 5 to 10 minutes as necessary ( 2.1)
- Intraocular surgery (Adrenalin<sup>®</sup> 1 mL vial only): Dilute 1 mL with 100 to 1000 mL of an ophthalmic irrigation fluid, for ophthalmic irrigation or intracameral injection ( 2.2)

-----  
**DOSAGE FORMS AND STRENGTHS**

Injection: 1 mg/mL (1:1000), 1 mL single-use vials ( 3)

-----  
**CONTRAINDICATIONS**

None ( 4)

-----  
**WARNINGS AND PRECAUTIONS**

- Do not use 30 mL vial for ophthalmic indication ( 5.1)
- Undiluted ophthalmic administration: associated with corneal endothelial damage ( 5.2)
- Do not inject into buttocks, digits, hands, or feet ( 5.3)
- Rare cases of serious skin and soft tissue infections have been reported following epinephrine injection. Advise patients to seek medical care if they develop signs or symptoms of infection. ( 5.4)
- May aggravate angina pectoris or produce ventricular arrhythmias, particularly in patients with underlying heart disease, administer with caution when used intramuscularly or subcutaneously ( 5.5)
- Patients with hyperthyroidism, Parkinson's disease, diabetes, and pheochromocytoma are at greater risk of having adverse reactions when used intramuscularly or subcutaneously ( 5.5)
- Presence of sulfite in this product should not deter use for anaphylaxis ( 5.6)

-----  
**ADVERSE REACTIONS**

Common adverse reactions to systemically administered epinephrine include anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and vomiting, headache, and respiratory difficulties. Arrhythmias, including fatal ventricular fibrillation, rapid rises in blood pressure producing cerebral hemorrhage, and angina have occurred ( 6.1)

**To report SUSPECTED ADVERSE REACTIONS, contact Par Pharmaceutical, Inc. at 1-800-828-9393 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

-----  
**DRUG INTERACTIONS**

- Sympathomimetic agents: possible additive effects ( 7)
- Cardiac glycosides, halogenated hydrocarbon anesthetics, or diuretics: observe for development of cardiac arrhythmias ( 7)
- Tricyclic antidepressants, MAO inhibitors, levothyroxine sodium, and certain antihistamines: potentiate effects of epinephrine ( 7)
- Beta-adrenergic blocking drugs: antagonize the cardiostimulating and bronchodilating effects of epinephrine ( 7)
- Alpha-adrenergic blocking drugs: antagonize the vasoconstricting and hypertensive effects of epinephrine ( 7)

- Ergot alkaloids may reverse the pressor response to epinephrine ( 7)

-----**USE IN SPECIFIC POPULATIONS**-----

Elderly patients and pregnant women may be at greater risk of developing adverse reactions when epinephrine is administered parenterally ( 8.1, 8.5)

**See 17 for PATIENT COUNSELING INFORMATION.**

**Revised: 9/2020**

---

**FULL PRESCRIBING INFORMATION: CONTENTS\***

**1 INDICATIONS AND USAGE**

- 1.1 Anaphylaxis (Adrenalin<sup>®</sup> 1 mL single-use)
- 1.2 Induction and Maintenance of Mydriasis during Intraocular Surgery (Adrenalin<sup>®</sup> 1 mL single-use vial only)

**2 DOSAGE AND ADMINISTRATION**

- 2.1 Anaphylaxis (Adrenalin<sup>®</sup> 1 mL single-use vials)
- 2.2 Induction and Maintenance of Mydriasis during Intraocular Surgery (Adrenalin<sup>®</sup> 1 mL single-use vial only)

**3 DOSAGE FORMS AND STRENGTHS**

**4 CONTRAINDICATIONS**

**5 WARNINGS AND PRECAUTIONS**

- 5.1 Potential for Ophthalmic Injury from Adrenalin<sup>®</sup> 30 mL multiple-dose vial
- 5.2 Injury with Undiluted Intraocular Solution
- 5.3 Incorrect Locations of Injection
- 5.4 Serious Infections at the Injection Site
- 5.5 Disease Interactions
- 5.6 Allergic Reactions Associated with Sulfite

**6 ADVERSE REACTIONS**

- 6.1 Adverse Reactions Associated with Intramuscular/Subcutaneous Use (for Anaphylaxis)
- 6.2 Adverse Reactions Associated with Intraocular Use (for Mydriasis)

**7 DRUG INTERACTIONS**

**8 USE IN SPECIFIC POPULATIONS**

- 8.1 Pregnancy
- 8.2 Labor and Delivery
- 8.3 Nursing Mothers
- 8.4 Pediatric Use
- 8.5 Geriatric Use

**10 OVERDOSAGE**

**11 DESCRIPTION**

**12 CLINICAL PHARMACOLOGY**

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

**13 NONCLINICAL TOXICOLOGY**

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

**16 HOW SUPPLIED/STORAGE AND HANDLING**

**17 PATIENT COUNSELING INFORMATION**

- Do not use
- When using this product do not
- Stop use and ask a doctor if
- Keep out of reach of children.

\* Sections or subsections omitted from the full prescribing information are not listed.

---

## **FULL PRESCRIBING INFORMATION**

### **1 INDICATIONS AND USAGE**

Adrenalin<sup>®</sup> is available as a single-use 1 mL vial. The 1 mL vial is for intramuscular, subcutaneous, and intraocular use.

#### **1.1 Anaphylaxis (Adrenalin<sup>®</sup> 1 mL single-use)**

Emergency treatment of allergic reactions (Type I), including anaphylaxis, which may result from allergic reactions to insect stings, biting insects, foods, drugs, sera, diagnostic testing substances and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. The signs and symptoms associated with anaphylaxis include flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with hypotension, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, airway swelling, laryngospasm, bronchospasm, pruritus, urticaria or angioedema, swelling of the eyelids, lips, and tongue.

#### **1.2 Induction and Maintenance of Mydriasis during Intraocular Surgery (Adrenalin<sup>®</sup> 1 mL single-use vial only)**

Induction and maintenance of mydriasis during intraocular surgery.

### **2 DOSAGE AND ADMINISTRATION**

#### **2.1 Anaphylaxis (Adrenalin<sup>®</sup> 1 mL single-use vials)**

Inject Adrenalin<sup>®</sup> intramuscularly or subcutaneously into the anterolateral aspect of the thigh, through clothing if necessary. When administering to a child, to minimize the risk of injection related injury, hold the leg firmly in place and limit movement prior to and during an injection. The injection may be repeated every 5 to 10 minutes as necessary. For intramuscular administration, use a needle long enough (at least 1/2 inch to 5/8 inch) to ensure the injection is administered into the muscle. Monitor the patient clinically for the severity of the allergic reaction and potential cardiac effects of the drug, with repeat doses titrated to effect. Do not administer repeated injections at the same site, as the resulting vasoconstriction may cause tissue necrosis.

Inspect visually for particulate matter and discoloration prior to administration. Do not use if the solution is colored or cloudy, or if it contains particulate matter.

Adults and Children 30 kg (66 lbs) or more: 0.3 to 0.5 mg (0.3 mL to 0.5 mL) of undiluted Adrenalin<sup>®</sup> administered intramuscularly or subcutaneously in the anterolateral aspect of the thigh, up to a maximum of 0.5 mg (0.5 mL) per injection, repeated every 5 to 10 minutes as necessary. Monitor clinically for reaction severity and cardiac effects.

Children less than 30 kg (66 lbs): 0.01 mg/kg (0.01 mL/kg) of undiluted Adrenalin<sup>®</sup> administered intramuscularly or subcutaneously in the anterolateral aspect of the thigh, up to a maximum of 0.3 mg (0.3 mL) per injection, repeated every 5 to 10 minutes as necessary. Monitor clinically for reaction severity and cardiac effects.

#### **2.2 Induction and Maintenance of Mydriasis during Intraocular Surgery (Adrenalin<sup>®</sup> 1 mL single-use vial only)**

Adrenalin<sup>®</sup> must be diluted prior to intraocular use. Dilute 1 mL of Adrenalin<sup>®</sup> 1 mg/mL (1:1000) in 100 to 1000 mL of an ophthalmic irrigation fluid to create an epinephrine concentration of 1:100,000 to 1:1,000,000 (10 mcg/mL to 1 mcg/mL). Use the irrigating solution as needed for the surgical procedure.

After dilution in an ophthalmic irrigating fluid, Adrenalin<sup>®</sup> may also be injected intracamerally as a bolus dose of 0.1 mL at a dilution of 1:100,000 to 1:400,000 (10 mcg/mL to 2.5 mcg/mL).

Inspect visually for particulate matter and discoloration prior to administration. Do not use if the solution is colored or cloudy, or if it contains particulate matter.

Note: The Adrenalin<sup>®</sup> 30 mL multiple-dose vial is not for ophthalmic use. USE ONLY THE ADRENALIN 1 ML SINGLE-USE VIAL FOR OPHTHALMIC USE.

### 3 DOSAGE FORMS AND STRENGTHS

Adrenalin<sup>®</sup> 1 mg/mL (1:1000) epinephrine injection, 1 mL solution in a single-use clear glass vial.

### 4 CONTRAINDICATIONS

None.

### 5 WARNINGS AND PRECAUTIONS

#### 5.1 Potential for Ophthalmic Injury from Adrenalin<sup>®</sup> 30 mL multiple-dose vial

The Adrenalin<sup>®</sup> 30 mL multiple-dose vial is not for ophthalmic use because it contains chlorobutanol which may be harmful to the corneal endothelium.

#### 5.2 Injury with Undiluted Intraocular Solution

The Adrenalin<sup>®</sup> 1 mL single-use vial, while it does not contain chlorobutanol, **must** be diluted before intraocular use. Epinephrine containing sodium bisulfite has been associated with corneal endothelial damage when used in the eye at undiluted concentrations (1 mg/mL) [ *see Dosage and Administration (2.2)*].

#### 5.3 Incorrect Locations of Injection

Injection into the anterolateral aspect of the thigh (vastus lateralis muscle) is the most appropriate location for administration because of its location, size, and available blood flow. Injection into (or near) smaller muscles, such as in the deltoid, is not recommended due to possible differences in absorption associated with this use.

Do not administer repeated injections of epinephrine at the same site, as the resulting vasoconstriction may cause tissue necrosis.

**Do not inject into buttock.** Injection into the buttock may not provide effective treatment of anaphylaxis and has been associated with the development of Clostridial infections (gas gangrene). Cleansing with alcohol does not kill bacterial spores, and therefore, does not lower this risk.

**Do not inject into digits, hands, or feet.** Epinephrine is a strong vasoconstrictor. Accidental injection into the digits, hands or feet may result in loss of blood flow to the affected area and has been associated with tissue necrosis.

#### 5.4 Serious Infections at the Injection Site

Rare cases of serious skin and soft tissue infections, including necrotizing fasciitis and myonecrosis caused by Clostridia (gas gangrene), have been reported at the injection site following epinephrine

injection for anaphylaxis. *Clostridium* spores can be present on the skin and introduced into the deep tissue with subcutaneous or intramuscular injection. While cleansing with alcohol may reduce presence of bacteria on the skin, alcohol cleansing does not kill *Clostridium* spores. To decrease the risk of *Clostridium* infection, do not inject Adrenalin<sup>®</sup> into the buttock [see *Warnings and Precautions (5.3)*]. Advise patients to seek medical care if they develop signs or symptoms of infection, such as persistent redness, warmth, swelling, or tenderness, at the epinephrine injection site.

## 5.5 Disease Interactions

Some patients may be at greater risk for developing adverse reactions after systemic epinephrine administration. Despite these concerns, the presence of these conditions is not a contraindication to epinephrine administration in an acute, life-threatening situation.

### Patients with Heart Disease

Epinephrine should be administered with caution in patients who have heart disease, including patients with cardiac arrhythmias, coronary artery or organic heart disease, cerebrovascular disease, or hypertension. In such patients, or in patients who are on drugs that may sensitize the heart to arrhythmias, epinephrine may precipitate or aggravate angina pectoris as well as produce ventricular arrhythmias. [ see *Drug Interactions (7) and Adverse Reactions (6.1)*].

### Other Patients and Diseases

Epinephrine should be administered with caution to patients with hyperthyroidism, Parkinson's disease, diabetes mellitus, pheochromocytoma, elderly individuals, and pregnant women. Patients with Parkinson's disease may experience psychomotor agitation or notice a temporary worsening of symptoms. Diabetic patients may experience transient increases in blood sugar.

## 5.6 Allergic Reactions Associated with Sulfite

Adrenalin<sup>®</sup> contains sodium bisulfite which may cause mild to severe allergic reactions including anaphylaxis or asthmatic episodes in susceptible individuals. However, the presence of bisulfite in this product should not preclude its use for the treatment of serious allergic or other emergency situations even if the patient is sulfite-sensitive, as the alternatives to using epinephrine in a life-threatening situation may not be satisfactory.

## 6 ADVERSE REACTIONS

### 6.1 Adverse Reactions Associated with Intramuscular/Subcutaneous Use (for Anaphylaxis)

Common adverse reactions to systemically administered epinephrine include anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and vomiting, headache, and respiratory difficulties. These symptoms occur in some persons receiving therapeutic doses of epinephrine, but are more likely to occur in patients with heart disease, hypertension, or hyperthyroidism [ see *Warnings and Precautions (5.5)*].

Due to the lack of randomized, controlled clinical trials of epinephrine for the treatment of anaphylaxis, the true incidence of adverse reactions associated with the systemic use of epinephrine is difficult to determine. Adverse reactions reported in observational trials, case reports, and studies are listed below by body system:

Cardiovascular: angina, arrhythmias, hypertension, pallor, palpitations, tachyarrhythmia, tachycardia, vasoconstriction, and ventricular ectopy.

Angina may occur in patients with coronary artery disease [ see *Warnings and Precautions (5.5)*].

Arrhythmias, including fatal ventricular fibrillation, have occurred, particularly in patients with underlying organic heart disease or patients receiving drugs that sensitize the heart to arrhythmias [ see

*Warnings and Precautions (5.5)*].

Rapid rises in blood pressure associated with epinephrine use have produced cerebral hemorrhage, particularly in elderly patients with cardiovascular disease [ *see Warnings and Precautions (5.5)*].

Respiratory: respiratory difficulties.

Neurological: dizziness , disorientation , excitability , headache , impaired memory , lightheadedness , nervousness , panic, psychomotor agitation, sleepiness , tingling , tremor, and weakness.

Psychiatric: anxiety, apprehensiveness, restlessness.

Gastrointestinal: nausea, vomiting.

Other:

Patients with Parkinson's disease may experience psychomotor agitation or a temporary worsening of symptoms [ *see Warnings and Precautions (5.5)*].

Diabetic patients may experience transient increases in blood sugar [ *see Warnings and Precautions (5.5)*].

Accidental injection into the digits, hands or feet may result in loss of blood flow to the affected area [ *see Warnings and Precautions (5.3)*]. Adverse events experienced as a result of an injection into these areas include increased heart rate, local reactions including injection site pallor, coldness, hypoesthesia, and tissue loss, or injury at the injection site resulting in bruising, bleeding, discoloration, erythema, and skeletal injury.

Injection into the buttock has resulted in cases of gas gangrene [ *see Warnings and Precautions (5.3)*].

Rare cases of serious skin and soft tissue infections, including necrotizing fasciitis and myonecrosis caused by Clostridia (gas gangrene), have been reported following epinephrine injection in the thigh [ *see Warnings and Precautions (5.4)* ] .

Skin: sweating.

## **6.2 Adverse Reactions Associated with Intraocular Use (for Mydriasis)**

Epinephrine containing sodium bisulfite has been associated with corneal endothelial damage when used in the eye at undiluted concentrations (1 mg/mL).

**To report SUSPECTED ADVERSE REACTIONS, contact Par Pharmaceutical, Inc. at 1-800-828-9393 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

## **7 DRUG INTERACTIONS**

Epinephrine should be administered cautiously to patients taking other sympathomimetic agents because of the possibility of additive effects.

Patients who are concomitantly receiving cardiac glycosides, digitalis, diuretics, quinidine, and other antiarrhythmics should be observed carefully for the development of cardiac arrhythmias [ *see Warnings and Precautions (5.5) and Adverse Reactions (6.1)*].

Administer epinephrine cautiously to patients receiving halogenated hydrocarbon general anesthetics, such as halothane, as coadministration may result in arrhythmias.

The effects of epinephrine may be potentiated by tricyclic antidepressants such as imipramine, monoamine oxidase inhibitors (MAOI), levothyroxine sodium, and certain antihistamines, notably diphenhydramine, tripelannamine, and dexchlorpheniramine.

The cardiostimulating and bronchodilating effects of epinephrine are antagonized by beta-adrenergic blocking drugs, such as propranolol.

The vasoconstricting and hypertensive effects of epinephrine are antagonized by alpha-adrenergic

blocking drugs, such as phentolamine.

Ergot alkaloids may reverse the pressor effects of epinephrine.

Epinephrine should not be used to counteract circulatory collapse or hypotension caused by phenothiazines, as a reversal of the pressor effects of epinephrine may result in further lowering of blood pressure.

## **8 USE IN SPECIFIC POPULATIONS**

### **8.1 Pregnancy**

Teratogenic Effects: Pregnancy Category C.

There are no adequate and well-controlled studies in pregnant women. Epinephrine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus (fetal anoxia, spontaneous abortion, or both). Epinephrine is teratogenic in rabbits, mice and hamsters dosed during organogenesis.

Epinephrine has been shown to have teratogenic effects (including gastroschisis and embryonic lethality) when administered subcutaneous in rabbits at approximately 15 times the maximum recommended intramuscular or subcutaneous dose (on a  $\text{mg}/\text{m}^2$  basis at a maternal subcutaneous dose of 1.2  $\text{mg}/\text{kg}/\text{day}$  for two to three days).

In mice, teratogenic effects (including embryonic lethality) were observed at approximately 3 times the maximum recommended intramuscular or subcutaneous dose (on a  $\text{mg}/\text{m}^2$  basis at maternal subcutaneous dose of 1  $\text{mg}/\text{kg}/\text{day}$  for 10 days). These effects were not seen in mice at approximately 2 times the maximum recommended daily intramuscular or subcutaneous dose (on a  $\text{mg}/\text{m}^2$  basis at a subcutaneous maternal dose of 0.5  $\text{mg}/\text{kg}/\text{day}$  for 10 days).

In hamsters, teratogenic effects were observed at approximately 2 times the maximum recommended intramuscular or subcutaneous dose (on a  $\text{mg}/\text{m}^2$  basis at a maternal subcutaneous dose of 0.5  $\text{mg}/\text{kg}/\text{day}$  for 4 days).

### **8.2 Labor and Delivery**

Use with caution during labor and delivery. Although epinephrine improves maternal hypotension associated with anaphylaxis, it may result in uterine vasoconstriction, decreased uterine blood flow, and fetal anoxia.

### **8.3 Nursing Mothers**

It is not known whether epinephrine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when epinephrine is administered to a nursing woman.

### **8.4 Pediatric Use**

Clinical use data support weight-based dosing for treatment of anaphylaxis in pediatric patients, and other reported clinical experience with the use of epinephrine suggests that the adverse reactions seen in children are similar in nature and extent to those both expected and reported in adults.

The safety and effectiveness of epinephrine (at a dilution of 1:100,000 to 1:400,000) for induction and maintenance of mydriasis during intraocular surgery have been established in pediatric patients. Use of Adrenalin<sup>®</sup> for induction and maintenance of mydriasis during intraocular surgery in pediatric patients is supported by adequate and well controlled studies in adults and uncontrolled studies in pediatric patients.

### **8.5 Geriatric Use**

Clinical studies for the treatment of anaphylaxis have not been performed in subjects aged 65 and over to determine whether they respond differently from younger subjects. However, other reported clinical experience with use of epinephrine for the treatment of anaphylaxis has identified that geriatric patients may be particularly sensitive to the effects of epinephrine. Therefore, for the treatment of anaphylaxis, consider starting with a lower dose to take into account potential concomitant disease or other drug therapy.

For induction and maintenance of mydriasis during intraocular surgery, no overall differences have been observed between elderly and other patients.

## 10 OVERDOSAGE

Overdosage of epinephrine may produce extremely elevated arterial pressure, which may result in cerebrovascular hemorrhage, particularly in elderly patients. Overdosage may also result in pulmonary edema because of peripheral vascular constriction together with cardiac stimulation. Treatment consists of a rapidly acting  $\alpha$ -adrenergic blocking drug and respiratory support.

Epinephrine is rapidly inactivated in the body and treatment following overdose with epinephrine is primarily supportive. If necessary, pressor effects may be counteracted by rapidly acting vasodilators or  $\alpha$ -adrenergic blocking drugs. If prolonged hypotension follows such measures, it may be necessary to administer another pressor drug.

Epinephrine overdosage can also cause transient bradycardia followed by tachycardia and these may be accompanied by potentially fatal cardiac arrhythmias. Premature ventricular contractions may appear within one minute after injection and may be followed by multifocal ventricular tachycardia (prefibrillation rhythm). Subsidence of the ventricular effects may be followed by atrial tachycardia and occasionally by atrioventricular block. Treatment of arrhythmias consists of administration of a beta-adrenergic blocking drug such as propranolol.

Overdosage sometimes results in extreme pallor and coldness of the skin, metabolic acidosis due to elevated blood lactic acid levels, and kidney failure. Suitable corrective measures must be taken in such situations.


Myocardial ischemia, myocardial infarction and cardiomyopathy have been noted in the literature following overdose of epinephrine.

## 11 DESCRIPTION

Adrenalin (epinephrine injection, USP) is a clear, colorless, sterile solution containing 1 mg/mL epinephrine, packaged as 1 mL of solution in a single dose clear glass vial. In the 1 mL vial, each 1 mL of Adrenalin solution contains 1 mg epinephrine, 7.3 mg sodium chloride, 0.457 mg sodium metabisulfite, 1 mg sodium hydroxide, 2.25 mg tartaric acid, 0.20 mg disodium edetate dihydrate, hydrochloric acid to adjust pH, and water for injection. The pH range is 2.2-5.0.

Epinephrine is a sympathomimetic catecholamine. The chemical name of epinephrine is: 1,2-Benzenediol, 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]-, or (-)-3,4-Dihydroxy- $\alpha$ -[2-(methylamino)ethyl]benzyl alcohol.

The chemical structure of epinephrine is:



The molecular weight of epinephrine is 183.2.

Epinephrine solution deteriorates rapidly on exposure to air or light, turning pink from oxidation to adrenochrome and brown from the formation of melanin.

## 12 CLINICAL PHARMACOLOGY

### 12.1 Mechanism of Action

Epinephrine acts on both alpha and beta-adrenergic receptors. The mechanism of the rise in blood pressure is 3-fold: a direct myocardial stimulation that increases the strength of ventricular contraction (positive inotropic action), an increased heart rate (positive chronotropic action), and peripheral vasoconstriction.

### 12.2 Pharmacodynamics

Epinephrine increases glycogenolysis, reduces glucose up take by tissues, and inhibits insulin release in the pancreas, resulting in hyperglycemia and increased blood lactic acid.

#### Intramuscular and subcutaneous use for anaphylaxis

Through its action on alpha-adrenergic receptors, epinephrine lessens the vasodilation and increased vascular permeability that occurs during anaphylaxis, which can lead to loss of intravascular fluid volume and hypotension.

Through its action on beta-adrenergic receptors, epinephrine causes bronchial smooth muscle relaxation and helps alleviate bronchospasm, wheezing and dyspnea that may occur during anaphylaxis.

Epinephrine also alleviates pruritus, urticaria, and angioedema and may relieve gastrointestinal and genitourinary symptoms associated with anaphylaxis because of its relaxer effects on the smooth muscle of the stomach, intestine, uterus and urinary bladder.

#### Intravenous use for hypotension associated with septic shock

When administered parenterally, epinephrine has a rapid onset and short duration of action.

Following intravenous administration of epinephrine, increases in systolic blood pressure and heart rate are observed. Decreases in systemic vascular resistance and diastolic blood pressure are observed at low doses of epinephrine because of  $\beta_2$ -mediated vasodilation, but are overtaken by  $\alpha_1$ -mediated peripheral vasoconstriction at higher doses leading to increase in diastolic blood pressure. The onset of blood pressure increase following an intravenous dose of epinephrine is < 5 minutes and the time to offset blood pressure response occurs within 15 minutes. Most vascular beds are constricted including renal, splanchnic, mucosal and skin.

Epinephrine causes mydriasis when administered parenterally.

### 12.3 Pharmacokinetics

Following intravenous injection, epinephrine is rapidly cleared from the plasma with an effective half-life of < 5 minutes. A pharmacokinetic steady state following continuous intravenous infusion is achieved within 10–15 minutes. In patients with septic shock, epinephrine displays dose-proportional pharmacokinetics in the infusion dose range of 0.03 to 1.7 mcg/kg/min.

Epinephrine is extensively metabolized with only a small amount excreted unchanged.

Epinephrine is rapidly degraded to vanillylmandelic acid, an inactive metabolite, by monoamine oxidase and catechol-O-methyltransferase that are abundantly expressed in the liver, kidneys and other extraneuronal tissues. The tissues with the highest contribution to removal of circulating exogenous epinephrine are the liver (32%), kidneys (25%), skeletal muscle (20%), and mesenteric organs (12%).

#### Specific Populations

##### *Elderly*

In a pharmacokinetic study of 45-minute epinephrine infusions given to healthy men aged 20 to 25 years and healthy men aged 60 to 65 years, the mean plasma metabolic clearance rate of epinephrine at steady state was greater among the older men (144.8 versus 78 mL/kg/min for a 0.0143 mcg/kg/min infusion).

## Body Weight

Body weight has been found to influence epinephrine pharmacokinetics. Higher body weight was associated with a higher plasma epinephrine clearance and a lower concentration plateau.

## 13 NONCLINICAL TOXICOLOGY

### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies to evaluate the carcinogenic potential of epinephrine have not been conducted.

Epinephrine and other catecholamines have been shown to have mutagenic potential *in vitro*. Epinephrine was positive in the *Salmonella* bacterial reverse mutation assay, positive in the mouse lymphoma assay, and negative in the *in vivo* micronucleus assay. Epinephrine is an oxidative mutagen based on the *E. coli* WP2 Mutoxitest bacterial reverse mutation assay. This should not prevent the use of epinephrine under the conditions noted under *Indications and Usage (1)*.

The potential for epinephrine to impair reproductive performance has not been evaluated, but epinephrine has been shown to decrease implantation in female rabbits dosed subcutaneously with 1.2 mg/kg/day (15-fold the highest human intramuscular or subcutaneous daily dose) during gestation days 3 to 9.

## 16 HOW SUPPLIED/STORAGE AND HANDLING

### Adrenalin 1 mg/mL Single Dose Vials:

Each carton contains 25 single dose vials containing 1 mg/mL Adrenalin (epinephrine injection, USP) solution in a 3 mL clear glass vial.

NDC 42023-159-01 1 mL Single Dose Vial

Discard unused portion.

Store between 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Epinephrine is light sensitive. Protect from light and freezing.

Inspect visually for particulate matter and discoloration prior to administration. Do not use the solution if it is colored or cloudy, or if it contains particulate matter.

## 17 PATIENT COUNSELING INFORMATION

Advise patients or their caregivers about common adverse reactions associated with the use of epinephrine including an increase in heart rate, the sensation of a more forceful heartbeat, palpitations, sweating, nausea and vomiting, difficulty breathing, pallor, dizziness, weakness or shakiness, headache, apprehension, nervousness, or anxiety. These symptoms and signs usually subside rapidly, especially with rest, quiet and recumbent positioning.

Warn patients with a good response to initial treatment about the possibility of recurrence of symptoms and instruct patients to obtain proper medical attention if symptoms return.

Warn patients with diabetes that they may develop increased blood glucose levels following epinephrine administration.

Rare cases of serious skin and soft tissue infections, including necrotizing fasciitis and myonecrosis caused by Clostridia (gas gangrene), have been reported at the injection site following epinephrine injection for anaphylaxis. Advise patients to seek medical care if they develop signs or symptoms of infection, such as persistent redness, warmth, swelling, or tenderness, at the epinephrine injection site [see Warnings and Precautions (5.2)] .

Distributed by:

**Par Pharmaceutical**

Chestnut Ridge, NY 10977

Adrenalin is a registered trademark of Par Pharmaceutical, Inc.

Registered Trademark No. 53,934

R01/19

OS159J-01-90-08

**Isopropyl Alcohol 70% Prep Pads**

**Active ingredient**

Isopropyl Alcohol 70% v/v

**Purpose**

Antiseptic

**Uses**

For first aid to decrease germs in

- minor cuts
- scrapes
- burns

For preparation of the skin prior to injection

**Warnings**

**For external use only**

**Flammable - keep away from fire or flame**

**Do not use**

with electrocautery procedures

**When using this product do not**

- get into eyes
- apply over large areas of the body
- in case of deep or puncture wounds, animal bites or serious burns consult a doctor

**Stop use and ask a doctor if**

- condition persists or gets worse or lasts for more than 72 hours
- do not use longer than 1 week unless directed by a doctor

**Keep out of reach of children.**

If swallowed, get medical help or contact a Poison Control Center right away.

**Directions**

- apply to skin as needed
- discard after single use

**Other information**

Protect from freezing and avoid excessive heat

**Inactive ingredient**

Water

**PRINCIPAL DISPLAY PANEL**

NDC: 76420-604-01

Rx Only

**Adyphren™ II Kit**

**Kit Contains**

- 2 Adrenalin® vial 1mg/mL (1:1000) 1mL
- 6 1mL safety syringe with 23G x 1” needle
- 8 Isopropyl alcohol 70% prep pad

Single Use Only

For Professional or Prescribed Use Only

Distributed by

**Enovachem™**

PHARMACEUTICALS

Torrance, CA 90501

NDC: 76420-604-01

Rx Only

# Adyphren™ II Kit

**Kit Contains**

- 2 Adrenalin\* vial 1mg/mL (1:1000) 1mL
- 6 1mL safety syringe with 23G x 1” needle
- 8 Isopropyl alcohol 70% prep pad

Single Use Only

For Professional or Prescribed Use Only

Distributed by  **Enovachem™**  
PHARMACEUTICALS  
Torrance, CA 90501

**ADYPHREN II KIT**

epinephrine and isopropyl alcohol kit

**Product Information**

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:76420-604
---------------------	-------------------------	---------------------------	---------------

**Packaging**

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:76420-604-01	1 in 1 CARTON; Type 1: Convenience Kit of Co-Package	10/04/2016	

**Quantity of Parts**

Part #	Package Quantity	Total Product Quantity
Part 1	2 VIAL	2 mL
Part 2	8 APPLICATOR	40 mL

**Part 1 of 2****ADRENALIN**

epinephrine injection

**Product Information**

Route of Administration	INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS
-------------------------	--

**Active Ingredient/Active Moiety**

Ingredient Name	Basis of Strength	Strength
EPINEPHRINE (UNII: YKH834O4BH) (EPINEPHRINE - UNII:YKH834O4BH)	EPINEPHRINE	1 mg in 1 mL

**Inactive Ingredients**

Ingredient Name	Strength
SODIUM CHLORIDE (UNII: 451W47IQ8X)	9 mg in 1 mL
SODIUM METABISULFITE (UNII: 4VON5FNS3C)	1 mg in 1 mL
HYDROCHLORIC ACID (UNII: QTT17582CB)	
WATER (UNII: 059QF0K00R)	

**Packaging**

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:42023-159-25	25 in 1 CARTON		
1		1 mL in 1 VIAL; Type 0: Not a Combination Product		

**Marketing Information**

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA204200	07/01/2013	

**Part 2 of 2**

# ISOPROPYL ALCOHOL

isopropyl alcohol swab

## Product Information

Route of Administration TOPICAL

## Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
ISOPROPYL ALCOHOL (UNII: ND2M416302) (ISOPROPYL ALCOHOL - UNII:ND2M416302)	ISOPROPYL ALCOHOL	70 mL in 100 mL

## Inactive Ingredients

Ingredient Name	Strength
WATER (UNII: 059QF0KO0R)	

## Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1		1 in 1 POUCH		
1		5 mL in 1 APPLICATOR; Type 0: Not a Combination Product		

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
OTC monograph not final	part333A	01/01/2007	

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
unapproved drug other		10/04/2016	

**Labeler** - Asclemed USA, Inc. (059888437)

Revised: 9/2020

Asclemed USA, Inc.